Ultrasound and Cisplatin Combined Treatment of Human Melanoma Cells A375—the Study of Sonodynamic Therapy

BERNARD, Vladan, Vojtěch MORNSTEIN, Jiřina ŠKORPÍKOVÁ and Josef JAROŠ. Ultrasound and Cisplatin Combined Treatment of Human Melanoma Cells A375—the Study of Sonodynamic Therapy. Ultrasound in Medicine and Biology. 2012, vol. 38, No 7, p. 1205-1211. ISSN 0301-5629. Available from: https://dx.doi.org/10.1016/j.ultrasmedbio.2012.02.006.

Basic information

• Original name: Ultrasound and Cisplatin Combined Treatment of Human Melanoma Cells A375—the Study of Sonodynamic Therapy
• Name in Czech: Kombinované působení ultrazvuku a cisplatiny na nádorové lidské buňky A375 - studie sonodynamického efektu
• Authors: BERNARD, Vladan (203 Czech Republic, guarantor, belonging to the institution), Vojtěch MORNSTEIN (203 Czech Republic, belonging to the institution), Jiřina ŠKORPÍKOVÁ (203 Czech Republic, belonging to the institution) and Josef JAROŠ (203 Czech Republic, belonging to the institution).
• Edition: Ultrasound in Medicine and Biology, 2012, 0301-5629.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 10610 Biophysics
• Country of publisher: Czech Republic
• Confidentiality degree: is not subject to a state or trade secret
• Impact factor: Impact factor: 2.455
• RIV identification code: RIV/00216224:14110/12:00060116
• Organization unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.1016/j.ultrasmedbio.2012.02.006
• UT WoS: 000304995600014
• Keywords in English: A375; cisplatin; ultrasound; viability

Abstract

Sonodynamic therapy, an effect of low-power ultrasound field and the anticancer drug cisplatin was studied in vitro on human melanoma cells A375. The viability of cells has been studied by standard MTT test according to different modes of treatment: application of cisplatin alone, exposure of ultrasound field alone, exposure to ultrasound followed by cisplatin, and application of cisplatin followed by exposure to ultrasound. Ultrasound was used at a therapeutical intensity of 1 Wcm-2 for 10 min. Concentration of cisplatin in the cell suspension was always 2,3 mikroM. The results show that sonodynamic therapy is one of the possibilities how to intensify standard cytostatic therapy. This conclusion is supported by reducing the viability of studied cells, especially 72 hours after the treatment. The time sequence of application of ultrasonic field and cytostatics appears to be a significant factor affecting the changes in cell’s viability. Maximum suppression of viability has been found when applying the experimental design involving application of cisplatin followed by exposure to ultrasound; the final value of viability of combined affected cells was more than ten percent lower than for alone cisplatin treatment.